Axogen director exercises options and sells shares
Axogen, Inc. director Amy McBride exercised an employee stock option for 13,353 shares of common stock at an exercise price of $14.85 per share and on the same date sold 13,353 shares of common stock at a weighted average price of $48.423 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Axogen, Inc. director Amy McBride exercised an employee stock option for 13,353 shares of common stock at an exercise price of $14.85 per share and on the same date sold 13,353 shares of common stock at a weighted average price of $48.423 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on May 12, 2026. All shares underlying the option had been fully vested since May 14, 2018.
Insider Trade Summary 10b5-1
Exercise and Sale: 13,353 shares ($448K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Wendell Amy McBride
Role
Director
Sold
13,353 shs ($647K)
Approx. gross sale proceeds
$647K
Approx. exercise cost
$198K
Approx. pre-tax spread
$448K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to purchase) F3 | 13,353 | $0.00 | $0.00 |
| Exercise | Common Stock | 13,353 | $14.85 | $198K |
| Sale | Common Stock F1, F2 | 13,353 | $48.423 | $647K |
Holdings After Transaction:
Employee Stock Option (right to purchase) — 0 contracts (Direct);
Common Stock — 107,976 shares (Direct)
Footnotes (3)
- F1. The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026.
- F2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F3. All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018.
Key Figures
Options exercised: 13,353 shares
Option exercise price: $14.85 per share
Shares sold: 13,353 shares
+3 more
6 metrics
Options exercised
13,353 shares
Employee Stock Option exercised on 2026-08-11
Option exercise price
$14.85 per share
Employee Stock Option for Axogen common stock
Shares sold
13,353 shares
Common stock sale on 2026-08-11
Weighted average sale price
$48.423 per share
Shares sold in multiple transactions, $47.82–$49.02 range
Option expiration date
2027-06-01
Expiration of exercised Employee Stock Option
10b5-1 plan adoption date
May 12, 2026
Rule 10b5-1 trading plan governing the sale
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, Employee Stock Option (right to purchase), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The reported price in Column 4 is a weighted average sale price."
Employee Stock Option (right to purchase) financial
"security_title: Employee Stock Option (right to purchase)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficial ownership financial
"full information regarding the number of shares purchased at each separate price"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Axogen (AXGN) director Amy McBride report in this Form 4?
Amy McBride reported exercising an employee stock option for 13,353 shares of Axogen common stock at $14.85 per share and selling 13,353 shares of common stock at a $48.423 weighted average price on August 11, 2026.
Was the Axogen (AXGN) insider sale by Amy McBride under a Rule 10b5-1 plan?
Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026. Such plans prearrange trades, providing structure independent of subsequent market conditions or nonpublic information.
What stock option did Amy McBride exercise in Axogen (AXGN)?
She exercised an Employee Stock Option covering 13,353 shares of Axogen common stock with an exercise price of $14.85 per share and an expiration date of June 1, 2027. The option was fully vested as of May 14, 2018.
Does this Axogen (AXGN) Form 4 show any remaining options after the exercise?
The reported derivative transaction shows 13,353 option shares exercised and 0 derivative shares remaining for that specific option award. The filing does not list additional derivative positions in its derivative summary table.
What is the nature of Amy McBride’s ownership in these Axogen (AXGN) transactions?
All reported transactions are coded as direct ownership. The Form 4 does not reference trusts, LLCs, or indirect holding entities in connection with these option exercises and stock sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
